Arax Advisory Partners’s Crinetics Pharmaceuticals CRNX Stock Holding History

Arax Advisory Partners’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$41K	Buy	1,097 +785	+252%	+$29.2K	﹤0.01%	3433
2026 Q1	$11.3K	Sell	312 -1,186	-79%	-$53K	﹤0.01%	2379
2025 Q4	$69.7K	Buy	1,498 +850	+131%	+$37.8K	﹤0.01%	1460
2025 Q3	$27K	Buy	648 +166	+34%	+$5.31K	﹤0.01%	2129
2025 Q2	$13.9K	Buy	482 +464	+2,578%	+$14.3K	﹤0.01%	1818
2025 Q1	$604	Buy	18 +12	+200%	+$448	﹤0.01%	2503
2024 Q4	$307	Buy	+6	New	+$336	﹤0.01%	2371

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Arax Advisory Partners's CRNX Position: Q2 2026 in Review

Arax Advisory Partners increased its Crinetics Pharmaceuticals (CRNX) stake by 252% in Q2 2026, buying an estimated $29.2K and bringing the position to 1,097 shares worth $41K. The position accounts for ﹤0.01% of the portfolio, ranked #3433.

Arax Advisory Partners first reported a position in CRNX in Q4 2024 and has held it in 7 quarters since. The position peaked at $69.7K in Q4 2025. 266 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

Arax Advisory Partners held 1,097 shares of Crinetics Pharmaceuticals worth $41K as of Q2 2026.
Arax Advisory Partners bought 785 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $29.2K.
Crinetics Pharmaceuticals made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3433 holding.
Arax Advisory Partners first reported a position in Crinetics Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
Arax Advisory Partners's Crinetics Pharmaceuticals position peaked at $69.7K in Q4 2025.
266 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.